T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape

References

• Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43(6):682–689.
   PubMed Web of Science ®Google Scholar
• 2021 1/25/2022. FDA approves first cell-based gene therapy for adult patients with multiple myeloma. In FDA news release. Food and drug administration. [cited 2022 Jan 25]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma.
   Google Scholar
• 2022 4/8/2022. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. [cited 2022 Apr 8]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma.
   Google Scholar
• Campbell KS, Cohen AD, Pazina T. Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma. Front Immunol. 2018;9:2551.
   PubMed Web of Science ®Google Scholar
• Joseph NS, Tai YT, Anderson KC, et al. Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor. Clin Pharmacol. 2021;13:169–180.
   PubMed Web of Science ®Google Scholar
• Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 2018;32(4):339–347.
   PubMed Web of Science ®Google Scholar
• Trabolsi A, Arumov A, Schatz JH. T Cell-Activating bispecific antibodies in cancer therapy. J Immunol. 2019;203(3):585–592.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9(2):182–212.
   PubMed Web of Science ®Google Scholar
• Liu H, Saxena A, Sidhu SS, et al. Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front Immunol. 2017;8:38–38.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Kumar SK. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update. Am J Hematol. 2022;97(1):99–118.
   PubMed Web of Science ®Google Scholar
• Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56–56.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• Sanford M. Blinatumomab: first global approval. Drugs. 2015;75(3):321–327.
   PubMed Web of Science ®Google Scholar
• Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126(14):3192–3201.
   PubMed Web of Science ®Google Scholar
• Topp MS, Duell J, Zugmaier G, et al. Anti–B-Cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38(8):775–783.
   PubMed Web of Science ®Google Scholar
• Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985–1005.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727–738.
   PubMed Web of Science ®Google Scholar
• Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225–3236.
   PubMed Web of Science ®Google Scholar
• Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, Munzert G, Einsele H. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775–783. doi: 10.1200/JCO.19.02657. Epub 2020 Jan 2. PMID: 31895611.
   Google Scholar
• Harrison SJ, Minnema MC, Lee HC, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-Cell maturation antigen (BCMA) Half-Life extended (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM). Blood. 2020;136(Supplement 1):28–29.
   Google Scholar
• Bahlis NJ, Raje NS, Costello C, et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). J Clin Oncol. 2021;39(15_suppl):8006–8006.
   Web of Science ®Google Scholar
• Sebag M, Raje NS, Bahlis NJ, et al. Elranatamab (PF-06863135), a B-Cell maturation antigen (BCMA) targeted CD3-Engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from magnetismm-1. Blood. 2021;138(Supplement 1):895–895.
   Google Scholar
• 2021 1/25/2022. Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma. Pfizer; 2022.
   Google Scholar
• Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665–674.
   PubMed Web of Science ®Google Scholar
• Moreau P, Usmani SZ, Garfall AL, et al. Updated results from MajesTEC-1: Phase 1/2 study of teclistamab, a B-Cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):896–896.
   Google Scholar
• Rodriguez-Otero P, Dholaria B, Askari E, et al. Subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma: results from a phase 1b multicohort study. Blood. 2021;138(Supplement 1):1647–1647.
   Google Scholar
• Madduri D, Rosko A, Brayer J, et al. REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):41–42.
   Google Scholar
• Zonder JA, Richter J, Bumma N, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1/2 first-in-Human study in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2021;138(Supplement 1):160–160.
   PubMedGoogle Scholar
• Rodriguez C, D'Souza A, Shah N, et al. Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-Cell redirecting antibody, in relapsed/refractory multiple myeloma. Blood. 2020;136(Supplement 1):43–44.
   Google Scholar
• Kumar S, D'Souza A, Shah N, et al. A phase 1 first-in-Human study of tnb-383B, a BCMA x CD3 bispecific T-Cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):900–900.
   Google Scholar
• Costa LJ, Wong SW, Bermúdez A, et al. First clinical study of the B-Cell maturation antigen (BCMA) 2 + 1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134(Supplement_1):143–143.
   Google Scholar
• Kodama T, Kochi Y, Nakai W, et al. Anti-GPRC5D/CD3 bispecific T-Cell-Redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. 2019;18(9):1555–1564.
   PubMed Web of Science ®Google Scholar
• Krishnan AY, Minnema MC, Berdeja JG, et al. Updated phase 1 results from MonumenTAL-1: First-in-Human study of talquetamab, a G Protein-Coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):158–158.
   Google Scholar
• Mancia SS, Farrell A, Louw K, et al. Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab (JNJ-64407564) for the treatment of relapsed and/or refractory multiple myeloma. Blood. 2021;138(Supplement 1):1658–1658.
   Google Scholar
• Chari A, Hari P, Bahlis NJ, et al. Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):161–161.
   Google Scholar
• Ovacik AM, Li J, Lemper M, et al. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties. mAbs. 2019;11(2):422–433.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Krishnan AY, Singhal S, et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J. 2019;9(2):17.
   PubMedGoogle Scholar
• Trudel S, Cohen AD, Krishnan AY, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138(Supplement 1):157–157.
   Google Scholar
• Hogan KA, Chini CCS, Chini EN. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10:1187.
   PubMed Web of Science ®Google Scholar
• Richter JR, Landgren CO, Kauh JS, et al. Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma. J Clin Oncol. 2018;36(15_suppl):TPS3132–TPS3132.
   Web of Science ®Google Scholar
• Zuch de Zafra CL, Fajardo F, Zhong W, et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin Cancer Res. 2019;25(13):3921–3933.
   PubMed Web of Science ®Google Scholar
• Lancman G, Richter J, Chari A. Bispecifics, trispecifics, and other novel immune treatments in myeloma. Hematology Am Soc Hematol Educ Program. 2020;2020(1):264–271.
   PubMedGoogle Scholar
• Madan S, Abdallah A-O, Cowan AJ, et al. An interim report on a phase 1/2 study of HPN217, a Half-Life extended Tri-Specific T cell activating construct (TriTAC ®) targeting B cell maturation antigen for the treatment of relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):1654–1654.
   Google Scholar
• Vrohlings M, Müller J, Jungmichel S, et al. Preclinical assessment of CDR101 – a BCMAxCD3xPD-L1 trispecific antibody with superior anti-Tumor efficacy. Blood. 2021;138(Supplement 1):1583–1583.
   PubMedGoogle Scholar
• 1/25/22. anti-CD38/CD28xCD3 trispecific T cell engager SAR442257. National Cancer Institute. [cited 2022 Jan 25]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd38-cd28xcd3-tri-specific-monoclonal-antibody-sar442257.
   Google Scholar
• Ochoa MC, Minute L, Rodriguez I, et al. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol. 2017;95(4):347–355.
   PubMed Web of Science ®Google Scholar
• Plesner T, Harrison SJ, Quach H, et al. A phase I study of RO7297089, a B-Cell maturation antigen (BCMA)-CD16a bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2021;138(Supplement 1):2755–2755.
   Google Scholar
• Gantke T, Reusch U, Kellner C, et al. AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma. J Clin Oncol. 2017;35(15_suppl):8045–8045.
   Google Scholar
• Ellwanger K, Reusch U, Fucek I, et al. Redirected optimized cell killing (ROCK®): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. mAbs. 2019;11(5):899–918.
   PubMed Web of Science ®Google Scholar
• Ross T, Reusch U, Wingert S, et al. Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma. Blood. 2018;132(Supplement 1):1927–1927.
   Google Scholar
• Kazandjian D, Landgren O. A new era of novel immunotherapies for multiple myeloma. The Lancet. 2021;398(10301):642–643.
   PubMed Web of Science ®Google Scholar
• Moreau P, Touzeau CT. Cell redirecting bispecific antibodies in multiple myeloma: a revolution? Blood. 2022;139(26):3681–3687.
   PubMed Web of Science ®Google Scholar
• Liu A. Bristol Myers hits CAR-T manufacturing bottleneck as Abecma demand outstrips supply; 2021. [2022 Mar 31]. Available from: https://www.fiercepharma.com/manufacturing/bristol-myers-hits-car-t-manufacturing-bottleneck-as-abecma-demand-outstrips-supply.
   Google Scholar
• Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–1596.
   PubMed Web of Science ®Google Scholar
• Landgren O, Hultcrantz M, Diamond B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7(6):862.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021 Dec 13:JCO2101935. doi: 10.1200/JCO.21.01935. Epub ahead of print. PMID: 34898239.
   Google Scholar
• Kazandjian D, Mo CC, Landgren O, et al. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol. 2020;191(5):692–703.
   PubMed Web of Science ®Google Scholar
• Aleman A, Upadhyaya B, Tuballes K, et al. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell. 2021;39(11):1442–1444.
   PubMed Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505.
   PubMed Web of Science ®Google Scholar